clinical trial · NCT06081894
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
Symptomatic Non-Obstructive Hypertrophic CardiomyopathyAficamtenPlacebo
brief summary
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
started
Aug 31, 2023
primary completion
Aug 1, 2026
completion
Oct 1, 2026
last updated
Aug 5, 2026
official title
A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol